Sarah Wellings, left, smiles with Isla Bell before her ANCA vasculitis diagnosis. (Photos courtesy of Sarah Wellings) This is Sarah Wellings’ story: Last night I dreamed I was running again. It seems my running days are over. Don’t get me wrong, I was no athlete when I was healthy,…
Jennifer Feinson Destours is an American with ANCA vasculitis living in Paris. This photo was taken two years post-diagnosis. (Photos courtesy of Jennifer Feinson Destours) This is Jennifer Feinson Destours’ story: My life has often been fantasized, the subject of envy. It sounds great, doesn’t it? An American moves…
AstraZeneca’s Fasenra (benralizumab), which is approved for a rare type of asthma, led to clinical remission in up to 70% of eosinophilic granulomatosis with polyangiitis (EGPA) patients taking the therapy off-label in the real-world setting. The therapy was also associated with a reduced daily dose of oral…
Rob Nelson explores Peggy’s Cove in Nova Scotia, Canada, in fall 2021. (Photos courtesy of Rob Nelson) This is Rob Nelson’s story: Receiving a vasculitis diagnosis has a dramatic effect physically, emotionally, and socially on both those with the disease and their families. Like many conditions,…
People with ANCA-associated vasculitis (AAV) who are positive for antibodies against both myeloperoxidase (MPO) and proteinase 3 (PR3) show a combination of clinical characteristics from patients with each antibody type, according to a recent study in China. While double-positive patients are generally more similar to those with MPO-ANCAs, particularly…
This is Pam Squires’ story: Pam Squires says her life with her wife, Sarah Jones, who has eosinophilic granulomatosis with polyangiitis (EGPA), is like having EGPA by proxy. (Courtesy of Sarah Jones) My wife, Sarah, and I attended a support group a while back and one of the care…
Sarah Jones smiles for the camera. (Photos courtesy of Sarah Jones) This is Sarah Jones’ story: I thought on the day of my EGPA diagnosis — fully, eosinophilic granulomatosis with polyangiitis — that I was finally going to get on top of it and move on. Nothing could…
Argenx has decided not to go ahead with its development plans for efgartigimod as a potential treatment for ANCA-associated vasculitis (AAV) after the therapy failed to show beneficial effects in late-stage clinical trials of two other autoimmune diseases. Efgartigimod is approved in the U.S. in two formulations for…
Karna Karlsrud, left, poses for a photo with her daughter, Clea, who has vasculitis. (Photos courtesy of Karna Karlsrud) This is Karna Karlsrud’s story: When I adopted my beautiful daughter, Clea, 23 years ago, the social worker told me in many conversations that fantasy is worse than reality, so…
A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Sana Biotechnology’s candidate CAR T-cell therapy SC291 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases has started enrollment. The study, GLEAM (NCT06294236), is recruiting up to 36 patients ranging in age from 18…
Get regular updates to your inbox.